Contamination of air, soil and water with pharmaceuticals and personal care products is currently 71 a major concern for many countries. Indeed, such contamination could endanger the health of 72 millionsof individuals, especially in the case of chronic and multiple exposures in sensitive 73 populations (Sanderson, 2011) . Regarding pharmaceuticals, it is noteworthy that the parent drugs 74 and their metabolites are excreted by patients as waste and some people also get rid of unused 75 pharmaceuticals in the toilets. Hence, all these pharmaceuticals can thereafter be found in water 76 (Kasprzyk-Hordern et al., 2008; Mompelat et al., 2009) . For instance, the following drugs were 77 detected in tap water in several independent studies: acetaminophen (APAP), bezafibrate and other 78 fibrates, caffeine, carbamazepine, cotinine (a nicotine metabolite), diazepam, diclofenac, 79 erythromycin, flumequine, ibuprofen, phenazone (antipyrine), roxithromycin, salicylic acid and 80 sulfamethoxazole (Daughton and Ternes, 1999; Halling-Sorensen et al., 1998; Heberer, 2002; 81 Mompelat et al., 2009; Stackelberg et al., 2004; Webb et al., 2003; Ye and Weinberg, 2007; Yu et 82 al., 2007; Zuccato et al., 2000) . As reported in most of these investigations, these drugs were found 83 in the drinking water at concentrations ranging generally between 1 and 20 ng/l. However, for some 84 pharmaceuticals such as APAP, caffeine, carbamazepine, fibrates, ibuprofen and phenazone, several 85 hundreds of ng/l were sometimes found in tap water (Daughton and Ternes, 1999; Mompelat et al., 86 2009) . 87
Long-term exposure to drug contaminants could have deleterious consequence for some 88 sensitive tissues, especially the liver. Indeed, liver expresses high levels of cytochromes P450 89 (CYPs) that can transform drugs into toxic metabolites, which are able to induce oxidative stress, 90 mitochondrial dysfunction and cell death (Aubert et al., 2012; Leung et al., 2012) . It is also worthy 91 to mention that recent investigations indicated that the liver could be particularly sensitive to drug-92 induced toxicity in the context of obesity (Aubert et al., 2012; Fromenty, 2013) . 93
Taken all these data into consideration, the aim of the present study was to determine the long-94 term hepatic effects of pharmaceutical contaminants in lean and obese ob/ob mice. These mice were 95 treated for 4 months with a mixture of 11 drugs provided in drinking water at concentrations ranging 96 from 10 to 10 6 ng/l. These drugs included APAP, caffeine, carbamazepine, cotinine, diclofenac, 97 erythromycin, ibuprofen, phenazone, roxithromycin, salicylic acid and sulfamethoxazole. 98 Importantly, all these molecules were previously detected in drinking water, as mentioned 99 previously. 100 5 aspartate aminotransferase (AST), total cholesterol, triglycerides and glucose levels were measured 135 on an automatic analyzer AU2700 (Olympus Diagnostics, Rungis, France) with Olympus 136 commercial Kits OSR6107, OSR6109, OSR6116, OSR6133 and OSR6121, respectively. 137 138 Liver histology. To evaluate necrosis, inflammation and steatosis, liver fragments were fixed in 10% 139 neutral formalin and embedded in paraffin. Then, 4-µm thick sections were cut and stained with 140 hematoxylin-eosin (H&E). All these sections were thoroughly examined by an experienced 141 pathologist (V.T.-S.). The amount of hepatic steatosis in ob/ob and the classification of this lesion 142 into 3 different categories (i.e. microvesicular, mediovesicular and macrovacuolar) were determined 143 as recently described (Trak-Smayra et al., 2011) Extraction and GeneSpring softwares (Agilent Technologies) and further analyzed using R-based 156 array tools, as previously described (Sulpice et al., 2013) . Agilent Feature Extraction Software was 157 used to read out and process the microarray image files. This software determines feature intensities 158 (including background subtraction), rejects outliers and calculates statistical confidences. Features 159 that were not positive and significant or below the background signal were filtered out. Microarray 160 data were normalized by using the 75 th percentile shift normalization algorithm. Differentially 161 expressed genes were identified by a two-sample univariate t-test and a random variance model as 162 previously described (Coulouarn et al., 2012) . Clustering analysis was done using Cluster 3.0 and 163 TreeView 1.6 with uncentered correlation and average linkage options. Enrichment for specific 164 biological functions or canonical pathways was evaluated by using gene ontology annotations, as 165 described previously (Coulouarn et al., 2012) . Gene set enrichment analysis (GSEA) was performed 166 using the Java-tool developed at the Broad Institute (Cambridge, MA, USA). Microarray data were 167 submitted to the gene expression omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo; 168 GSE49195). Body weight was measured on a regular basis for each mouse so that the gain of body weight 187 could be calculated over the 4-month period of treatment. Body weight was 31.2 ± 1.0 and 60.6 ± 188 1.0 g, respectively in untreated lean and obese mice at the end of the treatment. The gain of body 189 weight was higher in obese mice compared to lean mice and the treatment significantly modified 190 this parameter (Table 1 ). However, it was either decreased, unchanged or increased depending in the 191 different groups with no dose-dependent effect (Table 1) . 192 Some plasma parameters were measured at the end of the treatment. When compared to lean 193 mice, untreated ob/ob mice presented higher levels of plasma ALT, AST and total cholesterol but 194 normal levels of plasma triglycerides (Table 1) , as previously reported (Fromenty et al., 2009; 195 Lindström, 2007; Massart et al., 2012) . In addition, the obese mice did not present hyperglycemia 196 (Table 1) , which was consistent with previous data showing that the diabetic state of ob/ob mice 197 ameliorated with age (Fromenty et al., 2009; Lindström, 2007) . Interestingly, treatment with the 198 drug mixtures significantly modified the plasma levels of total cholesterol and ALT (Table 1) . This 199 was particularly evident in ob/ob mice treated with the cocktail containing 10 6 ng/l of each drug 200 since this group of animals presented the highest plasma levels of total cholesterol and ALT (Table  201 1). 202
Liver histology was also studied at the end of the treatment in mice treated or not with the 203 cocktails containing 10 5 and 10 6 ng/l of each drug. There were no histological alterations in lean 204 mice whatever the groups of animals (data not shown). Slight necroinflammation was observed in 205 untreated obese mice (data not shown), which could explain higher levels of plasma AST and ALT 206 (Begriche et al., 2008; Trak-Smayra et al., 2011) . However, treatment with the drug mixture did not 207 aggravate the histological score of necroinflammation (data not shown). 208
Hepatic steatosis was observed in all obese mice ( Supplementary Table 1 ) but this lesion was 209 absent in lean mice, treated or not with the cocktails (data not shown). Although the percentage of 210 hepatocytes with steatosis was unchanged by the treatment in ob/ob mice, a lower proportion of 211 microvesicular steatosis was observed in obese mice treated with the cocktail containing 10 6 ng/l of 212 each drug ( Supplementary Table 1 ). Accordingly, the fat droplets were larger in treated ob/ob mice 213 when compared to the controls (Fig. 1) . 214 215 Microarray analysis 216 8 Gene expression profiling was carried out in order to determine whether the cocktail containing 217 10 6 ng/l of each drug induced transcriptional changes in the livers of lean and obese mice. 218
Unsupervised microarray analysis demonstrated that the cocktail significantly modified the hepatic 219 expression of 280 and 284 genes (P<0.05; fold-change>1.5), respectively in lean and obese mice. 220
Among these genes, only 21 were dysregulated in both genotypes thus suggesting that drug-induced 221 transcriptional changes were tightly dependent of the genetic background. Table 2 provides the top 222 10 well-annotated genes that were up or down-regulated by the cocktail in lean and obese mice. 223
Interestingly, when a gene ontology analysis was performed, circadian rhythm was found as the 224 only functional category significantly enriched for the hepatic genes differentially expressed by the 225 cocktail in both lean and obese mice (Supplementary Table 2 ). In addition, this analysis indicated 226 that the functional categories were linked to biosynthetic processes and transcription factor activity 227 in lean mice and to cell cycle and cytoskeleton for ob/ob mice ( Supplementary Table 2 ). 228
Although this was not the main goal of this study, our unsupervised microarray analysis allowed us 229 to determine the differential hepatic gene expression between lean and ob/ob mice. Our analysis 230 identified 2,434 non-redundant genes that were differentially expressed between lean and obese 231 mice (P<0.001; fold-change>2; data not shown). As previously reported (Fromenty et al., 2009; 232 Yang et al., 2010) , ob/ob mice were characterized by an increased expression of many genes 233 involved in lipid synthesis, such as Elovl7 (x15.9), Scd2 (x12.7), Agpat9 ( referred to as Bmal1) (x0.42) and Cry1 (x0.28). Interestingly, a recent study carried out in ob/ob 238 mice reported lower hepatic expression of the last three genes compared to wild-type mice when the 239 animals were investigated at zeitgeber times similar to our investigations (i.e. zeitgeber times 2 to 6) 240 (Ando et al., 2011) . In order to validate the whole data set obtained from our microarray analysis, a 241 GSEA was performed using independent hepatic gene expression profiles from ob/ob and lean mice 242 (Sharma et al. 2010) , uploaded from the GEO database (GSE20878). Importantly, GSEA 243 demonstrated that up-and down-regulated genes in ob/ob livers identified in our study were 244 significantly enriched in the respective gene profiles of ob/ob and lean mice from the independent 245 GSE20878 dataset ( Supplementary Fig. 1) . 246 247 mRNA expression of specific genes 248 Some genes of interest were selected to determine by RT-qPCR their hepatic expression in mice 249 treated or not with the cocktail containing the 11 drugs at concentrations ranging from 10 to 10 6 250 ng/l. Since the gene ontology analysis pointed a specific dysregulation of genes involved in the 251 9 circadian rhythm in lean and obese mice, the expression of Bmal1, Clock, Dbp, Npas2, Per1, Per2, 252 Per3, and Cry1 was studied in all groups of mice. As shown in Fig. 2 , the drug cocktail presented a 253 significant effect on gene expression, which was either decreased (Bmal1, Clock, Npas2, Cry1) or 254 increased (Dbp, Per1, Per2, Per3). A clear dose-effect response was observed in lean and/or obese 255 mice for the expression of all these genes. Moreover, drug mixture and obesity presented an additive 256 effect on circadian gene expression. Importantly, the cocktail presented a significant effect on 257 Bmal1, Dbp, Npas2, Per2, Per3, and Cry1 expression when it contained as low as 10 2 and 10 3 ng/l 258 of each drug in the mixture (Fig. 2) . For these concentrations, it could be estimated that each drug 259 was administered to mice at the respective doses of 20 and 200 ng/kg/d, when considering the daily 260 intake of water and the body weight of the animals. 261
Because our gene expression profiling was performed on male mice solely, we next validated 262 our results on female mice. To this end, an independent series of lean and ob/ob female mice was 263 treated or not for 4 months with mixtures containing 10 4 , 10 5 and 10 6 ng/l of each drug, as described 264 in the Methods section. Interestingly, the profiles of drug-induced modification of circadian liver 265 gene expression were about similar to those observed in male mice, except for Per1 ( Fig. 3) . It was 266 noteworthy, however, that the effect of obesity on the hepatic expression of these genes was less 267 pronounced in female mice (Fig. 3 ) when compared to males (Fig. 2) . We also noticed that the liver 268 expression of the circadian genes was in general higher in female mice, especially in wild-type 269 animals ( Supplementary Fig. 2) , which was consistent with a recent study (Xu et al., 2012) . 270
Finally, we determined the hepatic expression of several genes not directly related to circadian 271 rhythm such as Alas1, Arrdc3, Mt1, Mt2, Usp2 and Atp2b2, the expression of which was found 272 dysregulated in the microarray analysis performed in male mice treated with the highest doses of the 273 drugs (Table 2) . Interestingly, a dose-effect response was in general observed for the expression of 274 these 6 genes (Fig. 4 ). However, in female mice, only the expression of Arrdc3 and Usp2 was found 275 to be comparable when compared to male mice (data not shown). This study showed for the first time that chronic oral exposure to low doses of pharmaceuticals 280 disturbed the hepatic expression of genes involved in circadian rhythm in mice. These 281 transcriptional effects were dose-dependent and particularly robust since they were found in lean 282 and obese male mice but also in female animals of both genotypes. In male mice, and to a lesser 283 extent in female mice, drug mixture and obesity presented an additive effect on the expression of 284 circadian genes such as Dbp, Per2 and Per3. Moreover, the expression of some circadian genes was 285 dysregulated when the drinking water contained the 11 drugs at concentrations as low as 10 2 and 10 3 286 ng/l. Such exposure corresponded to a daily intake of about 20 to 200 ng/kg/d. Hence, our data 287 indicated that a mixture of pharmaceutical contaminants can alter the expression of hepatic genes at 288 concentrations that can be found in drinking water. Indeed, for some drugs such as APAP, caffeine, 289 carbamazepine, ibuprofen and phenazone, several hundreds of ng/l were found in tap water in 290 previous studies (Daughton and Ternes, 1999; Mompelat et al., 2009 ). 291
A "whole mixture approach" was used in this study, and thus our investigations were not 292 designed to determine which drug(s) could be involved in these hepatic effects, in particular on the 293 expression of circadian genes. Nevertheless, it is noteworthy that some drugs such as prednisolone 294 have induced the genomic effects reported in our study, it is noteworthy that studies reporting 299 caffeine-induced altered hepatic expression of clock genes were performed with much higher doses 300 (from 3.5 to ca. 75 mg/kg/d) (Oike et al., 2011; Sherman et al., 2011) . Thus, further investigations 301 by treating mice with each drug separately would be needed to determine which component(s) of 302 the mixture could alter the liver expression of clock genes when administered at very low doses. 303
However, it is possible that the deleterious effects of the mixture uncovered in the present study 304 might have been less significant with each individual drug (or might not have been observed), as 305 suggested by some investigations in other experimental models (Christiansen et al., 2009; 306 Kortenkamp et al., 2007) . Interestingly, some of the drugs included in the cocktails belong to the 307 same pharmacological classes (mainly nonsteroidal anti-inflammatory drugs and antibiotics). 308
Therefore, it would be worth finding out whether the genomic effects detected in this study could be 309 attributed to a particular drug class. 310 11 Although the expression of hepatic genes was disturbed in mice treated for 4 months with the 311 cocktails containing 10 2 and 10 3 ng/l of each drug, these concentrations did not change the plasma 312 parameters assessed in this study, namely ALT, AST, glucose, triglycerides and total cholesterol. 313 Thus, the effects on gene expression observed in treated mice with these doses were not associated 314 with significant hepatic cytolysis and systemic alterations of lipid homeostasis. Therefore, changes 315 incircadian gene expression observed for these doses might not be functionally significant.It would 316 be interesting to determine whether a much longer exposure to these low concentrations of 317 pharmaceuticals could have harmful effects on liver biology and integrity beyond the alterations of 318 gene expression. Furthermore, some selected circadian genes (e.g. Bmal1, Per1, Per2) could be 319 useful markers for further investigations specifically designed to look for potential genomic effects 320 of individual drug (or subset of drugs) included in the mixture. 321
It is now acknowledged that disturbances of circadian rhythmicity can promote different 322 metabolic disorders and chronic diseases such as dyslipidemia, insulin resistance, obesity and 323 cardiovascular diseases (Duez and Staels, 2008; Maury et al., 2010; Prasai et al., 2008) . Moreover, 324 some studies showed that liver-specific deletion of genes involved in the liver clock could disturb 325 glucose and lipid homeostasis (Lamia et al., 2008; Tao et al., 2011) . In this study, however, the 326 genomic response to drug exposure was investigated only in the liver. Hence, further investigations 327 would be required to determine whether an altered expression of clock genes could also be observed 328 in other tissues such as the CNS and in tissues playing a key role in carbohydrate and lipid 329 homeostasis. Different time points of the light-dark cycle should also be studied during these 330
investigations. 331
In this study, the 4-month treatment with the cocktail containing 10 6 ng/l of each drug 332 significantly increased plasma ALT and total cholesterol and changed the pattern of hepatic 333 steatosis in ob/ob mice, whereas these effects were not observed in wild-type mice. For this dosage, 334 the hepatic expression of most circadian genes in ob/ob mice was the highest, or the lowest, among 335 the different groups of animals. Interestingly, the daily intake corresponding to this dose (ca. 0.2 336 mg/kg/d) was well below the pharmacological dosages for all drugs included in the mixture. Indeed, 337 the daily dosage of these drugs is comprised between a few mg/kg/d for diclofenac and 338 roxithromycin to 40 and 60 mg/kg/d for salicylic acid and APAP, respectively. Importantly, some of 339 these drugs such as APAP, diclofenac, ibuprofen and salicylate can be taken over the long-term (i.e. 340 several months) for the treatment of inflammatory diseases or chronic pain (Kuffner et al., 2006; 341 Schaffer et al., 2006) , which are often observed in obese patients (Guh et al. 2009; Wright et al. 342 2010) . Thus, our work could also be relevant for obese patients with multiple drug prescriptions, 343 since obesity appears to increase the risk of hepatotoxicity, at least for some drugs (Fromenty, 2013;  12 changes observed in this study could be involved in higher plasma ALT and total cholesterol 346 observed in ob/ob mice. 347
In conclusion, our study showed for the first time that chronic exposure to trace 348 pharmaceuticals was able to disturb the hepatic expression of genes involved in circadian rhythm in 349 lean and obese mice. This effect was dose-dependent and the expression of some circadian genes 350 was already dysregulated when the drinking water contained the 11 drugs at concentrations as low 351 as 10 2 and 10 3 ng/l. Moreover, drug mixture and obesity presented an additive effect on this gene 352 expression. Because some of the 11 drugs can be found in the drinking water at such concentrations 353 (e.g. APAP, caffeine, carbamazepine, ibuprofen, phenazone) further investigations would be needed 354 to determine whether our data could be extrapolated to human populations exposed to 355 pharmaceutical contaminants, in particular in countries with high prevalence of obesity. Catecholamine metabolic process. Oxidation-reduction process Hsd3b5 (0.18) Hydroxy-delta-5-steroid dehydrogenase, 3 beta-and steroid delta-isomerase 5 (NM_008295)
Oxidation-reduction process. Steroid biosynthetic process Man2a2 (0.40) Mannosidase 2, alpha 2 (NM_172903) Carbohydrate metabolic process. Mannose metabolic process Usp26 (0.45) Ubiquitin specific peptidase 26 (NM_031388)
